Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A new study shows that crosstalk between the ERBB2 and Hippo–YAP pathways is required for robust cardiac regeneration after myocardial infarction. ERBB2–ERK–YAP mechanotransduction signalling and epithelial–mesenchymal transition-like processes in cardiomyocytes can trigger regeneration even after functional deterioration and scarring.
A newly identified mechanism of piRNA-mediated post-transcriptional regulation of gene expression is associated with pathological hypertrophy, cardiac remodelling and heart failure.
Higher levels of angiotensin-converting enzyme 2 in plasma are associated with a greater risk of major cardiovascular disease events, according to a global, population-based study.
A new single-cell data set defines the immune response to myocardial infarction, from origins in the bone marrow and its translational potential in the blood to diversification and regulation within the heart.
The disparities amplified by the COVID-19 pandemic present disturbing evidence that we are far from cardiovascular health-care equity. Individuals, leaders and institutions must prioritize research, policies and structures to advance diversity, equity, inclusion and belonging — Diversity 4.0, a justice imperative, essential to advancing workforce excellence and cardiovascular health.
The cellular composition of the heart is highly heterogeneous, plastic and sex-specific. These findings have important implications for understanding the functional specialization of the heart and also highlight the importance of considering biological sex in preclinical studies.
A new study shows that exosomes secreted by cardiac cells derived from human induced pluripotent stem cells improve myocardial recovery without arrhythmogenic complications and might provide an acellular therapeutic option for myocardial infarction.
A network of macrophages in the heart supports cardiac health and function by removing dysfunctional mitochondria and waste material released from cardiomyocytes in subcellular particles called exophers.
A study in an in vitro model of RBM20-deficient dilated cardiomyopathy suggests that pharmacological upregulation of RBM20 with all-trans retinoic acid is a potential therapeutic strategy in patients with a heterozygous RBM20 mutation.
Mavacamten, a first-in-class cardiac myosin inhibitor, reduces symptoms and improves health status in patients with obstructive hypertrophic cardiomyopathy, according to findings from the EXPLORER-HCM trial.
Anti-inflammatory therapy with low-dose colchicine reduces the risk of cardiovascular events by 31% compared with placebo in patients with chronic coronary artery disease, according to findings from the LoDoCo2 trial presented at the ESC Congress 2020.
A strategy of early rhythm control for patients with recently diagnosed atrial fibrillation reduces the risk of cardiovascular events compared with usual care, according to findings from the EAST-AFNET 4 trial.
Empagliflozin, an SGLT2 inhibitor, reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with reduced ejection fraction with or without diabetes mellitus, according to findings from the EMPEROR-Reduced trial.
Findings from the ATPCI trial show that trimetazidine is safe but not protective against angina and cardiac events in the long term after percutaneous coronary intervention.
According to findings from the POPular TAVI trial, in patients without an indication for oral anticoagulation, the use of aspirin alone compared with aspirin plus clopidogrel after transcatheter aortic valve implantation significantly reduced bleeding rates and did not increase thromboembolic events.
